NCT00651768View on ClinicalTrials.gov

Titratable Dosing in Moderate to Severe Asthmatics

PHASE3CompletedINTERVENTIONAL

Enrollment

570

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

January 31, 2005

Conditions

Asthma

Interventions

DRUG

budesonide/formoterol

DRUG

Symbicort pMDI + budesonide HFA pMDI

Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY